{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T13:58:17Z","timestamp":1777039097227,"version":"3.51.4"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["YDZJ202201ZYTS126"],"award-info":[{"award-number":["YDZJ202201ZYTS126"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Atypical hemolytic uremic syndrome (aHUS) is a rare thrombotic microangiopathy (TMA) caused by dysregulation of the complement system. It is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Owing to its diverse and nonspecific clinical manifestations, early diagnosis of the condition is challenging and typically requires excluding other TMA-related conditions, such as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome caused by <jats:italic>Escherichia coli<\/jats:italic> infection. Accurate diagnosis relies on the recognition of typical TMA symptoms, laboratory testing, and the exclusion of other conditions. Treatments typically include plasma exchange, supportive care, and complement-targeted therapy. Eculizumab, a complement component 5 inhibitor, plays a crucial role in aHUS treatment in severe cases as well as when traditional interventions fail. In this case report, we described a female Han Chinese patient who developed aHUS following an upper respiratory tract infection, initially presented with intermittent seizures, and received treatment with eculizumab, plasma exchange, and hemodialysis. The patient ultimately remained dialysis-dependent; however, they achieved complete remission for other systemic complications of aHUS. We emphasized in this case report the importance of timely diagnosis and treatment of aHUS as well as the potential value of eculizumab in improving patient outcomes. Furthermore, successful treatment and follow-up results provide insights into the management of this rare disease, including long-term dialysis requirements and disease monitoring after remission. Thus, clinicians can better understand the clinical manifestations of aHUS and its associated diagnostic challenges, treatment strategies, and long-term management needs.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1542973","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T05:38:14Z","timestamp":1744090694000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of atypical hemolytic uremic syndrome with eculizumab in a patient presenting with neuropsychiatric prodrome: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Hanze","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonggao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017860","article-title":"How I diagnose and treat atypical hemolytic uremic syndrome","volume":"141","author":"Fakhouri","year":"2023","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009280","article-title":"Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study","volume":"137","author":"Fakhouri","year":"2021","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01481-6","article-title":"Ravulizumab: a review in atypical haemolytic uraemic syndrome","volume":"81","author":"Syed","year":"2021","journal-title":"Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/CLEP.S245642","article-title":"Epidemiology of atypical hemolytic uremic syndrome: a systematic literature review","volume":"12","author":"Yan","year":"2020","journal-title":"Clin Epidemiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-709865","article-title":"and atypical HUS","volume":"129","author":"Jokiranta Ts.","year":"2017","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0902814","article-title":"Atypical hemolytic-uremic syndrome","volume":"361","author":"Noris","year":"2009","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"bcr2017219716","DOI":"10.1136\/bcr-2017-219716","article-title":"Complement factor B mutation-associated aHUS and myocardial infarction","volume":"2017","author":"Noronha","year":"2017","journal-title":"BMJ Case Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00467-015-3076-8","article-title":"An international consensus approach to the management of atypical hemolytic uremic syndrome in children","volume":"31","author":"Loirat","year":"2016","journal-title":"Pediatr Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2017050518","article-title":"Factor H competitor generated by gene conversion events associates with atypical hemolytic uremic syndrome","volume":"29","author":"Goicoechea de Jorge","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/humu.21256","article-title":"Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome","volume":"31","author":"Maga","year":"2010","journal-title":"Hum Mutat"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2016.10.005","article-title":"Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference","volume":"91","author":"Goodship","year":"2017","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1055\/s-0034-1375297","article-title":"Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment","volume":"40","author":"Hofer","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/S1474-4422(15)00253-7","article-title":"The diagnosis of posterior reversible encephalopathy syndrome","volume":"14","author":"Ng","year":"2015","journal-title":"Lancet Neurol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00111-8","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions","volume":"14","author":"Fugate","year":"2015","journal-title":"Lancet Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02431-5","article-title":"Neurological manifestations of thrombotic microangiopathy syndromes in adult patients","volume":"51","author":"Weil","year":"2021","journal-title":"J Thromb Thrombolysis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2022.43.71.36406","article-title":"Atypical haemolytic uremic syndrome with posterior reversible encephalopathy syndrome in an adolescent: a rare case report","volume":"43","author":"Kenjale","year":"2022","journal-title":"Pan Afr Med J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2018.12.034","article-title":"Seizure as the presenting symptom for atypical hemolytic uremic syndrome","volume":"56","author":"Chan","year":"2019","journal-title":"J Emerg Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27461","article-title":"Successful 13-year ongoing remission with C5 inhibitor therapy following renal transplant in atypical hemolytic uremic syndrome","volume":"99","author":"Mostafa","year":"2024","journal-title":"Am J Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"13126","DOI":"10.2215\/CJN.01090209","article-title":"Complement inhibitor eculizumab in atypical hemolytic uremic syndrome","volume":"4","author":"Mache","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-558296","article-title":"Dynamics of complement activation in aHUS and how to monitor eculizumab therapy","volume":"124","author":"Noris","year":"2014","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-016-0288-3","article-title":"Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment","volume":"30","author":"Walle","year":"2017","journal-title":"J Nephrol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.03.884","article-title":"Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults","volume":"6","author":"Barbour","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.01.035","article-title":"The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome na\u00efve to complement inhibitor treatment","volume":"97","author":"Rondeau","year":"2020","journal-title":"Kidney Int"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1092860","article-title":"Hemolytic uremic syndrome in the setting of COVID-19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature","volume":"11","author":"Mato\u0161evi\u0107","year":"2023","journal-title":"Front Pediatr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Kulasekararaj","year":"2019","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003812","article-title":"How I treat paroxysmal nocturnal hemoglobinuria","volume":"137","author":"Brodsky","year":"2021","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04760512","article-title":"Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults","volume":"8","author":"Fremeaux-Bacchi","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.13581021","article-title":"How I treat complement-mediated TMA","volume":"17","author":"Sperati","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2024.06.022","article-title":"Non-plasmapheresis approaches for managing severe renal thrombotic microangiopathy: a report of 7 cases","volume":"85","author":"Frimat","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-007252","article-title":"Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome","volume":"108","author":"Caprioli","year":"2006","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1542973\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T05:38:16Z","timestamp":1744090696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1542973\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":32,"alternative-id":["10.3389\/fimmu.2025.1542973"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1542973","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"article-number":"1542973"}}